Overview

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Status:
ENROLLING_BY_INVITATION

Trial end date:
2028-06-13

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the long-term safety, tolerability, and efficacy of sonelokimab in participants with moderate to severe hidradenitis suppurativa who were previously enrolled in a parental study.

Phase:

PHASE3

Details

Lead Sponsor:

MoonLake Immunotherapeutics AG

Treatments:

sonelokimab